ITRM20080310A1 - Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines. - Google Patents
Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines.Info
- Publication number
- ITRM20080310A1 ITRM20080310A1 IT000310A ITRM20080310A ITRM20080310A1 IT RM20080310 A1 ITRM20080310 A1 IT RM20080310A1 IT 000310 A IT000310 A IT 000310A IT RM20080310 A ITRM20080310 A IT RM20080310A IT RM20080310 A1 ITRM20080310 A1 IT RM20080310A1
- Authority
- IT
- Italy
- Prior art keywords
- human
- epithelial
- markers
- sensitivity
- serves
- Prior art date
Links
- 101000877404 Homo sapiens Protein enabled homolog Proteins 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 title 1
- 102000048778 human Enah Human genes 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000310A ITRM20080310A1 (it) | 2008-06-12 | 2008-06-12 | Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines. |
| PCT/IB2008/053023 WO2009150494A1 (en) | 2008-06-12 | 2008-07-28 | Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human cancer cells |
| CA2737141A CA2737141A1 (en) | 2008-06-12 | 2008-07-28 | Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human cancer cells |
| US12/997,795 US20120028252A1 (en) | 2008-06-12 | 2008-07-28 | Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human cancer cells |
| EP08789467.1A EP2304051B1 (en) | 2008-06-12 | 2008-07-28 | Human mena isoform serve as marker for sensitivity to egfr inhibition in human cancer cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000310A ITRM20080310A1 (it) | 2008-06-12 | 2008-06-12 | Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITRM20080310A1 true ITRM20080310A1 (it) | 2009-12-13 |
Family
ID=40220246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000310A ITRM20080310A1 (it) | 2008-06-12 | 2008-06-12 | Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120028252A1 (it) |
| EP (1) | EP2304051B1 (it) |
| CA (1) | CA2737141A1 (it) |
| IT (1) | ITRM20080310A1 (it) |
| WO (1) | WO2009150494A1 (it) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011115271A1 (ja) * | 2010-03-18 | 2011-09-22 | 大日本住友製薬株式会社 | 腫瘍血管新生阻害剤 |
| WO2012020281A1 (en) | 2010-08-11 | 2012-02-16 | Istituti Fisioterapici Ospitalieri (Ifo) - Istituto Regina Elena Per Lo Studio E La Cura Dei Tumori | New markers for the epithelial and proliferative or mesenchymal invasive phenotype of human neoplasias |
| US20140220018A1 (en) * | 2011-06-16 | 2014-08-07 | Giovanni M. Pitari | Biomarkers for epithelial cancer diagnosis and treatment |
| EP2973802B1 (en) * | 2013-03-12 | 2023-08-30 | Apple Inc. | High voltage, high volumetric energy density li-ion battery using advanced cathode materials |
| US10243242B2 (en) * | 2013-12-20 | 2019-03-26 | Daikin Industries, Ltd. | Electrolytic solution, electrochemical device, lithium-ion secondary cell, and module |
| JP2019500591A (ja) * | 2015-11-13 | 2019-01-10 | マサチューセッツ・インスティトュート・オブ・テクノロジー | がん細胞を検出及び修飾するための方法及び組成物 |
| CN109475631A (zh) | 2016-07-08 | 2019-03-15 | 迈特斯泰公司 | 用于靶向mena蛋白同种型激酶的抗癌疗法的方法和组合物 |
| WO2020006394A1 (en) * | 2018-06-29 | 2020-01-02 | The Jackson Laboratory | Breast cancer splice variants |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972615A (en) * | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6972324B2 (en) * | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
-
2008
- 2008-06-12 IT IT000310A patent/ITRM20080310A1/it unknown
- 2008-07-28 EP EP08789467.1A patent/EP2304051B1/en not_active Not-in-force
- 2008-07-28 CA CA2737141A patent/CA2737141A1/en not_active Abandoned
- 2008-07-28 US US12/997,795 patent/US20120028252A1/en not_active Abandoned
- 2008-07-28 WO PCT/IB2008/053023 patent/WO2009150494A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20120028252A1 (en) | 2012-02-02 |
| WO2009150494A1 (en) | 2009-12-17 |
| EP2304051A1 (en) | 2011-04-06 |
| CA2737141A1 (en) | 2009-12-17 |
| EP2304051B1 (en) | 2015-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150223T8 (hr) | Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za lijeäśenje glioblastoma (gbm-a) i drugih karcinoma | |
| EP2449498A4 (en) | CONTENT DELIVERY AND REVENUE PAYMENT | |
| SI2240572T1 (sl) | Uporaba RNA za reprogramiranje somatskih celic | |
| BRPI1004572A2 (pt) | "fusões genéticas recorrentes em câncer | |
| DK3130923T3 (da) | Terapeutiske fremgangsmåder i forbindelse med cancerstamceller | |
| EP2060040A4 (en) | USE OF PHRASE TOKENS IN TRANSACTIONS | |
| HRP20170908T1 (hr) | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice | |
| DK2223696T3 (da) | Mesenkymale CD34- stamceller til anvendelse i sårhelings-genterapi | |
| PL2881402T3 (pl) | Ekspresja zmutowanej ROS w ludzkim raku wątroby | |
| SI3192529T1 (sl) | Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev | |
| BRPI1013771A2 (pt) | "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." | |
| IL238669A (en) | Extended soluble ph20 polypeptides and uses thereof | |
| DK2127652T3 (da) | Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination | |
| DK2249859T3 (da) | Behandling af metastatisk prostatacancer med degarelix | |
| HRP20160551T8 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| BRPI1009281A2 (pt) | composição oftálmica tópica | |
| DK3147373T3 (da) | Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer | |
| PL2350647T3 (pl) | Sposób identyfikacji selekcji i analizy komórek nowotworowych | |
| BRPI0909817A2 (pt) | uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos | |
| BRPI0912723A2 (pt) | aprovação de transferência monetária via dispositivo móvel | |
| BR112012003103A2 (pt) | tratamento de células de astrócitos tumorais com inibidor de receptores de endotelina | |
| BRPI1011520A2 (pt) | aba com reborbos de sali~encia e reentrância. | |
| SMT201400158B (it) | Derivati eteroaromatici di fenilimidazolo come inibitori dell'enzima pde10a | |
| BR112013014115A2 (pt) | conjugados de fornecimento de polinucleotídeos in vivo apresentando ligações enzimáticas sensíveis | |
| NO20091267L (no) | Sammensetninger og fremgangsmåter for å forebygge kreft med cupredoxiner |